A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults

Trial Profile

A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Pfs25 malaria vaccine MVI (Primary) ; Aluminium hydroxide
  • Indications Malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 Treatment arms changed from 1 arm to 4 arms with different doses of vaccine.
    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top